GlaxoSmithKline Pharmaceuticals Limited
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. GlaxoSmithKline Pharmaceuticals Limited's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5% to $34,537,062,000. The net income raised on $5,899,610,000 and profit margin reached 17%. Total operating expenses were $7,383,024,000.
Profit Margin
| 2011 | 23.78B | 4.28B | 18.02% |
|---|---|---|---|
| 2012 | 26.54B | 5.61B | 21.17% |
| 2013 | 25.54B | 4.81B | 18.85% |
| 2015 | 26.38B | 3.81B | 14.45% |
| 2016 | 27.63B | 3.76B | 13.64% |
| 2018 | 28.71B | 3.50B | 12.21% |
| 2019 | 31.28B | 4.45B | 14.24% |
| 2021 | 31.98B | 3.58B | 11.2% |
| 2022 | 32.78B | 3.80B | 11.62% |
| 2024 | 34.53B | 5.89B | 17.08% |
GLAXO.NS Income Statement (2011 – 2023)
| 2023 | 2021 | 2020 | 2018 | 2017 | 2015 | 2014 | 2013 | 2013 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 34.53B | 32.78B | 31.98B | 31.28B | 28.71B | 27.63B | 26.38B | 25.54B | 26.54B | 23.78B |
Cost of revenue | 14.19B | 14.49B | 13.94B | 14.44B | 13.27B | 13.33B | 12.25B | 12.29B | 11.56B | 9.19B |
Gross profit | 20.33B | 18.28B | 18.04B | 16.83B | 15.43B | 14.30B | 14.12B | 13.25B | 14.97B | 14.59B |
Operating exp. | ||||||||||
Research and development | 25.43M | 18.28M | 18.07M | 23.26M | 22.52M | 19.95M | 17.54M | 0 | 0 | 0 |
Selling and marketing | 1.79B | 1.83B | 1.71B | 2.05B | 1.54B | 1.91B | 1.10B | 1.93B | 1.66B | 0 |
Total operating expenses | 7.38B | 11.29B | 11.53B | 11.27B | 10.67B | 9.65B | 9.66B | 8.05B | 6.97B | 5.31B |
Operating income | 13.60B | 7.69B | 7.61B | 6.53B | 5.24B | 4.64B | 4.88B | 5.19B | 7.99B | 9.27B |
Other income (expenses), net | -5.44B | 99.04M | -5.01B | 295.58M | 634.71M | 1.16B | -2.83B | 1.91B | 349.49M | 0 |
Income before tax | 8.16B | 7.79B | 5.50B | 6.82B | 5.39B | 5.79B | 6.04B | 7.11B | 8.34B | 9.27B |
Income tax expense | 2.26B | 3.98B | 1.92B | 2.37B | 1.89B | 2.02B | 2.23B | 2.29B | 2.72B | 3.05B |
Net income | 5.89B | 3.80B | 3.58B | 4.45B | 3.50B | 3.76B | 3.81B | 4.81B | 5.61B | 4.28B |
Earnings per share | ||||||||||
Basic EPS | 34.83 | 22.48 | 21.14 | 26.29 | 20.7 | 22.21 | 22.5 | 28.44 | 33.17 | 25.3 |
Diluted EPS | 34.83 | 22.48 | 21.14 | 26.29 | 20.7 | 22.21 | 22.5 | 28.44 | 33.17 | 25.3 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |